GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
| Revenue (TTM) | $156.12M |
| Gross Profit (TTM) | $76.94M |
| EBITDA | $-360.50M |
| Operating Margin | -332.90% |
| Return on Equity | -16.10% |
| Return on Assets | -11.40% |
| Revenue/Share (TTM) | $4.07 |
| Book Value | $60.79 |
| Price-to-Book | 1.19 |
| Price-to-Sales (TTM) | 19.28 |
| EV/Revenue | 14.05 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 28.10% |
| Shares Outstanding | $42.92M |
| Float | $33.47M |
| % Insiders | 5.23% |
| % Institutions | 83.52% |
Volatility is currently contracting
New class action for Grail, Inc. (GRAL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/4/2026
SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025 and February 19, 2026, both dates inclusive (the “Class Period”), have until Tuesday, August 4, 2026 to seek appointment as lead plaintiff of the Grail class action lawsuit. Captioned Robbins v.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Grail To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Grail between May 13, 2025 and February 19, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Grail, Inc. ("Grail" or the "Company") (NASDAQ: GRAL) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds GRAIL, Inc. (“GRAIL” or the “Company”) (NASDAQ: GRAL) investors of the August 4, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The GRAIL Class Action Lawsuit : Do you, or did you, own shares of GRAIL, Inc. (NASDAQ: GRAL)?
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”), of the important August 4, 2026 lead plaintiff deadline.
SAN FRANCISCO, July 08, 2026 (GLOBE NEWSWIRE) -- On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired shares of GRAIL common stock between May 13, 2025 and February 19, 2026.
New York, New York--(Newsfile Corp. - July 8, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Grail securities between May 13, 2025 and February 19, 2026, both dates inclusive (the "Class Period").
BENSALEM, Pa., July 8, 2026 /PRNewswire/ -- The Law Offices of Howard G.
From Optimism to Disillusionment: How Investor Sentiment in Grail Shifted as NHS-Galleri Confidence Crumbled, Costing Shareholders $51.32 Per Share NEW YORK, July 8, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP provides context on investor sentiment surrounding Grail, Inc. (NASDAQ: GRAL) and a pending securities class action filed on behalf of shareholders who purchased securities between May 13, 2025 and February 19, 2026. Find out if you can recover your Grail investment losses or contact Joseph E.
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in GRAIL, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit.
